Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer

NCT01396707 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT01396707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01396707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
March 31, 2019
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive gastric cancer, metastatic or recurrent gastric adenocarcinoma